Article
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
Leukemia - 1 Jan 2025
Jacoby Meagan A, Duncavage Eric D, Khanna Ajay, Chang Gue Su, Nonavinkere Srivatsan Sridhar, Miller Christopher A, Gao Feng, Robinson Josh, Shao Jin, Fulton Robert S, Fronick Catrina C, O'Laughlin Michelle, Heath Sharon E, Brendel Kimberly, Chavez Monique, DiPersio John F, Abboud Camille N, Stockerl-Goldstein Keith, Westervelt Peter, Cashen Amanda, Pusic Iskra, Oh Stephen T, Welch John S, Wells Denise A, Loken Michael R, Uy Geoffrey L, Walter Matthew J
Abstract excerpt
Accurate assessment of therapy response in myelodysplastic neoplasm (MDS) has been challenging. Directly monitoring mutational disease burden may be useful, but is not currently included in MDS response criteria, and the correlation of mutational burden and traditional response endpoints is not completely understood. Here, we used genome-wide and targeted next-generation sequencing (NGS) to monitor clonal and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
